Search PubMed⌕ Search

Biomedical subjects

H Kohri

Publications and source records attributed to H Kohri.

32 records · Page 2Linked to original sources
PubMed1992

Determination of absorption and endogenous excretion of iron in man by monitoring fecal excretion of a stable iron isotope (58Fe).

The absorption and endogenous excretion of iron in man was studied by monitoring the fecal excretion of a stable iron isotope (58Fe). The study was carried out for 12 healthy volunteers who were divided into two groups. Group I received 58Fe-labeled ferric ammonium citrate (III) (58FeAC) equivalent to 6 mg of iron as a control, and group II received a combination of 500 mg of vitamin C and 58FeAC. A new formula was used to calculate the 58Fe absorption ratio reflecting the pool of iron in the intestinal cells, and the ratio was compared with that obtained from Janghorbani's formula, which has been used as one of the common methods. As a result, the 58Fe absorption ratio in group II was statistically significantly higher than that of group I (34.4 +/- 6.1% vs. 15.0 +/- 5.5%, M +/- SD) using Janghorbani's formula. The similar absorption ratio (34.1 +/- 6.0% vs. 14.8 +/- 5.5%) was also obtained by our new formula. Our results confirmed the previous findings that the availability of iron is stimulated by the supplementation of vitamin C. Both formulae agreed in the absorption of iron, indicating that the endogenous excretion of iron (caused by the desquamated cells) in the intestine does not disguise the iron absorption.

Absorption↗
PubMed1990

Practical debittering using model peptides and related compounds.

In order to develop a practical debittering method for amino acids and peptides, several debittering methods were studied. The authors found that hooking acidic amino acids to and acetylation of bitter amino acids is very effective to remove the bitterness from their concentrated solution. For debittering by mixing with additives, skin milk and other peptide compounds were effective. Acidic amino acids were also effective to reduce the bitterness. Gelatinized starch was found to be useful for debittering because it takes bitter substances into its net structure.

Amino Acid Sequence↗
PubMed1987

Exercise-induced changes in branched chain amino acid/aromatic amino acid ratio in the rat brain and plasma.

Central fatigue was induced by running rats on a treadmill. Amino acid and ammonia metabolism in the brain and blood were followed with time to correlate its changes with physical exhaustion. The blood ammonia level did not change during running, but was prominently increased at exhaustion. The brain level of ammonia was also prominently high at the end of exercise with a time course of change similar to that of the blood level. Plasma concentrations of branched chain amino acids (BCAA) and aromatic amino acids (AAA) increased as the animals continued to run; however, the plasma BCAA/AAA ratio was definitely depressed at exhaustion. This was also true with the brain BCAA/AAA ratio. A positive correlation was demonstrated between the plasma and brain BCAA/AAA ratios at r=0.5040 and P less than 0.05. These exercise-related changes suggest that physical exercise-induced central fatigue involves not only an increase in brain ammonia, but also a disturbance in brain amine metabolism accompanying plasma and brain BCAA/AAA ratio depression. Furthermore, the ammonia level and BCAA/AAA ratio in the brain correlated with those in the blood. It is reasonable to consider that the blood ammonia concentration and plasma BCAA/AAA ratio may serve as important indices of the clinical condition of exercise-induced central fatigue.

Amino Acids↗
PubMed1986

[Study of the ameliorating effects of an enteral nutrient for liver failure on hepatic encephalopathy: effects of SF-1008C on plasma and brain free amino acids, intracerebral amine concentrations and electroencephalogram in portacaval shunted rats with ammonia loading].

The ameliorating effects of an enteral nutrient for liver failure (SF-1008C), which is enriched with branched-chain amino acids (BCAA) and includes few aromatic amino acids (AAA), were investigated. The blood ammonia, plasma and brain free amino acids, intracerebral amine concentrations and electroencephalogram were measured in portacaval shunted rats with 10% ammonium acetate (3 ml/kg, i.p.) (PCS) as a model of hepatic encephalopathy. The blood ammonia and plasma free amino acid concentrations in PCS rats were significantly increased in comparison to sham-operated (Sham) rats. Thus, the plasma BCAA/AAA ratio in PCS rats was appreciably reduced. Concomitant with the abnormal plasma amino acid concentrations, the brain free amino acid concentrations in PCS rats were markedly increased in comparison to the Sham rats. Moreover, the intracerebral tryptophan (Trp) and 5-hydroxyindol acetic acid (5-HIAA) concentrations were significantly increased, and the intracerebral dopamine (DA) concentration was significantly decreased in the PCS rats. The intracerebral serotonin (5-HT) and norepinephrine (NE) concentrations were, however, hardly changed. A smaller voltage for the electroencephalogram was used in the PCS rats than in the Sham rats. Abnormal plasma and brain free amino acid concentrations in PCS rats were normalized by oral administration of SF-1008C, and the low voltage electroencephalograms in the PCS rats were suppressed. On the other hand, abnormal plasma and brain free amino acid concentrations in the PCS rats were hardly normalized by oral administration of ED-AC, an elemental diet based on an amino acid composition of egg protein. These results suggest that SF-1008C affects brain free amino acids, intracerebral amine concentrations and electroencephalogram by ameliorating abnormal plasma free amino acid concentrations. Moreover, there is a highly significant correlation between the plasma BCAA/AAA ratio and the brain BCAA/AAA ratio, and this finding suggests that the plasma free amino acid patterns reflect the brain free amino acid patterns.

Amino Acids↗
PubMed1977

Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.

The pharmacokinetics of 5-(3-tert.-butylamino-2-hydroxy)-propoxy-3,4-dihydrocarbostyril hydrochloride (carteolol hydrochloride, OPC-1085) have been investigated in man following single or repetitive oral administration. The plasma half-lives. The plasma half-lives of carteolol at single doses of 10, 15 and 30 mg were 5.4, 5.5 and 5.0 h, respectively. The amounts of carteolol excreted into urine within 24 h at the same dose levels accounted for 64, 70 and 76% of the respective doses. The half-lives obtained by the Sigmaminus method were 5.6, 5.6 and 5.4 h, respectively, being essentially consistent with the aforementioned plasma half-lives of carteolol after administration at 15 mg daily for 7 successive days were determined to be 5.54 h on the 1st day and 6.91 h on the 7th day, displaying the increase in half-life value with the repetitive dosing. While, the predicted value determined using the experimental value on the 1st day agreed with the experimental value on the 7th day. Furthermore, the amounts of carteolol excreted in the urine were not significantly different between the 1st and 7th days. The 7-day repetitive administration with carteolol brought about the steady state of plasma levels. It was concluded from these results that carteolol has little ability to accumulate in man.

Adrenergic beta-Antagonists↗
PubMed1976

[Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic agent. (3) Autoradiographic total body distribution studies in mice].

Distribution of a new beta-adrenergic blocking agent, 3H-carteolol in mice was studied by whole body autoradiography. The distribution of radioactivity was observed in all organs except the eyes and brain, with particularly high specific activities in the kidneys, liver, gall bladder and content in the intestines within a short time after either oral or intravenous administration. The radioactivity was then promptly eliminated from all tissues and organs, and excreted almost entirely in the urine and bile. Propranolol is known to be distributed at a high concentration in the brain, whereas the concentration of (3H-) carteolol detectable in the brain was slight. In the adrenal gland, the radioactivity was localized in the medulla. Radioactivity was detected also in the stomach contents after the intravenous administration. The distribution of radioactivity in the fetus through the placenta was less than that in the major organs of the mother mouse, and the elimination of the activity was more rapid in the fetus than in mother. These findings indicate that carteolol and its metabolites do to some extent pass through the blood-brain barrier and placenta.

Adrenergic beta-Antagonists↗